← Back to Search

Other

EDP-235 200mg for Coronavirus (SPRINT Trial)

Q: Are there any restrictions for participants in this trial?

<p>Eligible patients must have contracted <a href="https://www.withpower.com/clinical-trials/covid">covid</a>-19 within the last 5 days and present with at least 2 symptoms of moderate severity. In addition, participants must be between 18-64 years old and have a confirmed SARS-CoV-2 infection.</p>

Phase 2

Recruiting

Research Sponsored by Enanta Pharmaceuticals, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 1 through day 33

Awards & highlights

SPRINT Trial Summary

This trial tests a drug to treat mild-moderate COVID-19 in adults outside the hospital.

Eligible Conditions

Coronavirus
COVID-19

SPRINT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 1 through day 33

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 1 through day 33

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 through day 33 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety as measured by frequency of adverse events (AEs)

Secondary outcome measures

Change from baseline in COVID-19 signs/symptom

Change from baseline in SARS-CoV-2 RNA viral load

Change from baseline in infectious SARS- CoV-2 viral load

+6 more

SPRINT Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: EDP-235 400mgExperimental Treatment1 Intervention

Once a day orally for 5 days

Group II: EDP-235 200mgExperimental Treatment1 Intervention

Once a day orally for 5 days

Group III: PlaceboPlacebo Group1 Intervention

Once a day orally for 5 days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

EDP-235

2022

Completed Phase 1

~140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Enanta Pharmaceuticals, IncLead Sponsor

39 Previous Clinical Trials

2,784 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any patients still needed for this experiment?

"That is correct. Based on the information available on clinicaltrials.gov, it appears as though this trial is still recruiting patients. The listing was first posted on November 10th, 2022 and was last edited on November 11th, 2022. They are hoping to enroll 200 individuals from a total of 10 different sites."

Answered by AI

Are patients of all ages being accepted for this trial?

"Eligibility requirements state that potential participants for this trial must between 18-64 years old."

Answered by AI

What is the cap on the number of patients who can be enrolled in this clinical trial?

"In order to move forward, this clinical study needs 200 participants that meet the pre-specified inclusion criteria. These individuals can enrol at locations such as Carolina Research Center in Shelby, North carolina and MedBio Trials in Miami, Florida."

Answered by AI

Are there any dangers to taking EDP-235 200mg?

"While there is some data suggesting that EDP-235 200mg is safe, it only received a score of 2 because there is no evidence pointing to the medication's efficacy."

Answered by AI

How many locations are conducting this experiment?

"There are a total of 13 sites for this study, which include Carolina Research Center in Shelby, North carolina, MedBio Trials in Miami, Florida, SMS Clinical Research LLC in Mesquite, Texas."

Answered by AI

Are there any restrictions for participants in this trial?

"Eligible patients must have contracted covid-19 within the last 5 days and present with at least 2 symptoms of moderate severity. In addition, participants must be between 18-64 years old and have a confirmed SARS-CoV-2 infection."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

2022. "A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05616728.